# In Silico Comparison of Rifampicin and 25-desacetyl Rifampicin-Induced PXR-Mediated CYP450 Transcriptional Response in 3D Primary Human Hepatocytes

**Authors:** Ellen Tanaka Kahiya, Tomáš Smutný, Lucie Smutná, Jurjen Duintjer Tebbens, Petr Pávek, Veronika Bernhauerová

PMC · DOI: 10.1007/s11538-026-01619-1 · Bulletin of Mathematical Biology · 2026-03-06

## TL;DR

This study compares how two forms of rifampicin affect liver enzyme activity in human cells using mathematical models and gene analysis.

## Contribution

The study introduces a novel in silico approach to compare PXR-mediated CYP450 transcriptional responses between rifampicin and its metabolite.

## Key findings

- 25-DRIF activates PXR at a rate 20 times lower than RIF.
- CYP3A4 transcription rate constants were higher in 25-DRIF-treated cells compared to RIF-treated cells.
- CYP2C9 transcription rate constants were similar in RIF- and 25-DRIF-treated cells.

## Abstract

The pregnane X receptor (PXR) regulates the expression of cytochrome P450 (CYP) enzymes and plays a crucial role in the metabolism of various drugs. Rifampicin (RIF) is a PXR ligand that forms the primary metabolite, 25-desacetyl rifampicin (25-DRIF), which retains the antimicrobial activity of the original drug. In this study, we quantified PXR activation and its associated effects on CYP3A4, CYP2C9, and CYP2B6 enzymes in response to 25-DRIF treatment by combining mathematical modeling with long-term mRNA expression analysis of these enzymes in 3D primary human hepatocyte (3D PHH) spheroids. Our estimates suggest that 25-DRIF activates PXR at a rate 20 times lower than RIF. The PXR-dependent rate constant for CYP3A4 transcription was estimated to be higher in 3D PHHs treated with 25-DRIF than in those treated with RIF and also higher than that for CYP2B6 transcription in 3D PHHs treated with 25-DRIF. The rate constants driving PXR-dependent transcription of CYP2C9 were comparable in RIF- and 25-DRIF-treated 3D PHHs. These results demonstrate the ligand-specific nature of PXR activation and suggest that the transcription of PXR-controlled CYP enzymes is ligand- and CYP-specific in 3D PHHs. Finally, we showed that the half-maximal effective concentration (\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hbox {EC}_{50}$$\end{document}EC50) evaluated from our mathematical predictions was time-dependent, which was further validated by CYP3A4 gene reporter assays that measured RIF-induced PXR activity.

The online version contains supplementary material available at 10.1007/s11538-026-01619-1.

## Linked entities

- **Genes:** CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576], CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559], CYP2B6 (cytochrome P450 family 2 subfamily B member 6) [NCBI Gene 1555]
- **Proteins:** NR1I2 (nuclear receptor subfamily 1 group I member 2)
- **Chemicals:** Rifampicin (PubChem CID 135398735), 25-desacetyl Rifampicin (PubChem CID 135542225)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, RHOF (ras homolog family member F, filopodia associated) [NCBI Gene 54509] {aka ARHF, RIF}, MC5R (melanocortin 5 receptor) [NCBI Gene 4161] {aka MC2}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, Nr1i2 (nuclear receptor subfamily 1, group I, member 2) [NCBI Gene 84385] {aka PXR}, CYP2B6 (cytochrome P450 family 2 subfamily B member 6) [NCBI Gene 1555] {aka CPB6, CYP2B, CYP2B7, CYPIIB6, EFVM, IIB1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, AADAC (arylacetamide deacetylase) [NCBI Gene 13] {aka CES5A1, DAC}, NR1I2 (nuclear receptor subfamily 1 group I member 2) [NCBI Gene 8856] {aka BXR, ONR1, PAR, PAR1, PAR2, PARq}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}
- **Diseases:** liver cancer (MESH:D006528), PHHs (MESH:D015459)
- **Chemicals:** DMSO (MESH:D004121), Lipofectamine (MESH:C086724), dexamethasone (MESH:D003907), RIF (MESH:D012293), 25-DRIF (MESH:C032393), Chemicals (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MC3 — Mus musculus (Mouse), Hybridoma (CVCL_A2IT), MC1 — Mus musculus (Mouse), Hybridoma (CVCL_A2IR), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), p3A4 — Homo sapiens (Human), Hepatitis C infection, Cancer cell line (CVCL_0C53)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963181/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963181/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963181/full.md

---
Source: https://tomesphere.com/paper/PMC12963181